1naresh<pre>Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh<pre>Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => OpenAccess
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
PT  - JOURNAL ARTICLE
AU  - Tateishi, K.
AU  - Tateishi, U.
AU  - Nakanowatari, S.
AU  - Ohtake, M.
AU  - Minamimoto, R.
AU  - Suenaga, J.
AU  - Murata, H.
AU  - Kubota, K.
AU  - Inoue, T.
AU  - Kawahara, N.
TI  - &lt;sup&gt;62&lt;/sup&gt;Cu-Diacetyl-Bis (N&lt;sup&gt;4&lt;/sup&gt;-Methylthiosemicarbazone) PET in Human Gliomas: Comparative Study with [&lt;sup&gt;18&lt;/sup&gt;F]Fluorodeoxyglucose and L-Methyl-[&lt;sup&gt;11&lt;/sup&gt;C]Methionine PET
AID  - 10.3174/ajnr.A3679
DP  - 2014 Feb 01
TA  - American Journal of Neuroradiology
PG  - 278--284
VI  - 35
IP  - 2
4099  - http://www.ajnr.org/content/35/2/278.short
4100  - http://www.ajnr.org/content/35/2/278.full
SO  - Am. J. Neuroradiol.2014 Feb 01; 35
AB  - BACKGROUND AND PURPOSE: 62Cu-diacetyl-bis(N4-methylthiosemicarbazone) was developed as a hypoxic radiotracer in PET. We compared imaging features among MR imaging and 62Cu-diacetyl-bis(N4-methylthiosemicarbazone)-PET, FDG-PET, and L-methyl-[11C]methionine)-PET in gliomas. MATERIALS AND METHODS: We enrolled 23 patients who underwent 62Cu-diacetyl-bis(N4-methylthiosemicarbazone)-PET and FDG-PET and 19 (82.6%) who underwent L-methyl-[11C]methionine)–PET, with all 23 patients undergoing surgery and their diagnosis being then confirmed by histologic examination as a glioma. Semiquantitative and volumetric analysis were used for the comparison. RESULTS: There were 10 newly diagnosed glioblastoma multiforme and 13 nonglioblastoma multiforme (grades II and III), including 4 recurrences without any adjuvant treatment. The maximum standardized uptake value and tumor/background ratios of 62Cu-diacetyl-bis(N4-methylthiosemicarbazone), as well as L-methyl-[11C]methionine, were significantly higher in glioblastoma multiforme than in nonglioblastoma multiforme (P = .03 and P = .03, respectively); no significant differences were observed on FDG. At a tumor/background ratio cutoff threshold of 1.9, 62Cu-diacetyl-bis(N4-methylthiosemicarbazone) was most predictive of glioblastoma multiforme, with 90.0% sensitivity and 76.9% specificity. The positive and negative predictive values, respectively, for glioblastoma multiforme were 75.0% and 85.7% on 62Cu-diacetyl-bis(N4-methylthiosemicarbazone), 83.3% and 60.0% on L-methyl-[11C]methionine, and 72.7% and 75.0% on MR imaging. In glioblastoma multiforme, volumetric analysis demonstrated that 62Cu-diacetyl-bis(N4-methylthiosemicarbazone) uptake had significant correlations with FDG (r = 0.68, P = .03) and L-methyl-[11C]methionine (r = 0.87, P = .03). However, the 62Cu-diacetyl-bis(N4-methylthiosemicarbazone)–active region was heterogeneously distributed in 50.0% (5/10) of FDG-active and 0% (0/6) of L-methyl-[11C]methionine)–active regions. CONCLUSIONS: 62Cu-diacetyl-bis(N4-methylthiosemicarbazone) may be a practical radiotracer in the prediction of glioblastoma multiforme. In addition to FDG-PET, L-methyl-[11C]methionine)–PET, and MR imaging, 62Cu-diacetyl-bis(N4-methylthiosemicarbazone)-PET may provide intratumoral hypoxic information useful in establishing targeted therapeutic strategies for patients with glioblastoma multiforme. 62Cu-ATSM62Cu-diacetyl-bis(N4-methylthiosemicarbazone)GBMglioblastoma multiformeMETL-methyl-[11C]methioninenon-GBM gliomasWorld Health Organization grade II and III gliomasSUVmaxmaximum standardized uptake valueT/B ratiotumor/background ratio